EQL Pharma Investor Relations

Welcome to EQL Pharma's Investor Pages!

We strive to have an open and proactive dialogue with our shareholders.
Read More

Interim Report Q3 2023/2024 (in Swedish)

Listen to CEO Axel Schörling present EQL Pharma's latest report (in Swedish)
Interim Report Q3 2023/2024

Press Releases

EQL Pharma's CEO increases his holding in the company

EQL Pharma's CEO, Axel Schörling, has increased his stake in the company. During the period 22-24 May, Axel Schörling has bought 53,903 shares in the Company at a volume-weighted average price of S...

Year-end Report April 2023 – March 2024


Good growth and record amount of launches January - March 2024 · Consolidated sales during the fourth quarter, January to March amounted to SEK 78.1 (60.3) million, an increase of 30%. Adjusted...

Se all

EQL Pharma in Short

EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.
Read more about us

Financial Calendar


Annual Report 2023/24


Interim Report Q1


Annual general meeting